
Contents

Part I Multimodal Approach to Colorectal Cancer

Clinically Relevant Study End Points in Rectal Cancer.	3
1 Introduction.	4
2 End Points in Phase I Trials	6
3 End Points in Phase II Neoadjuvant Rectal Cancer Trials	7
3.1 Pathological Parameters of Response	8
3.2 Imaging Response	12
4 Endpoints in Phase III Trials.	13
4.1 Disease-Free Survival and Local Recurrence	15
4.2 The Need for Long-Term Follow-Up	15
5 Discussion.	16
References	16

Neoadjuvant Treatment in Rectal Cancer: Do We Always Need Radiotherapy or Can We Risk Assess Locally Advanced Rectal Cancer Better?	21
1 Introduction.	22
2 Late Effects of Radiotherapy.	23
3 Local Recurrence.	24
3.1 Is Neoadjuvant Chemotherapy an Alternative?	26
3.2 Can Radiotherapy be Omitted?	26
3.3 Are There Clearly Distinguishable Groups Who Do Not Need RT?	26
4 Conclusion	32
References	33

Treatment Dilemmas in Patients with Synchronous

Colorectal Liver Metastases	37
1 Introduction	38
2 Patients with Asymptomatic Cancer of the Colon and Unresectable Synchronous Liver Metastases	38
2.1 Results of Initial Treatment with Chemotherapy	39
2.2 Results of Initial Resection of the Primary Tumor	40
2.3 The Effect of Treatment Strategy on Overall Survival	42
3 Patients Presenting with Resectable Synchronous Liver Metastases and Rectal Cancer	43
3.1 Results of Staged or Simultaneous Rectal and Liver Resection Combined with Perioperative Radiotherapy and Chemotherapy	44
3.2 Enhancing Efficacy of Perioperative Radiotherapy and Chemotherapy	44
3.3 Results of the Liver-First Approach	45
References	46

Part II Improving Treatment of Pancreatic Cancer

Pancreatic Surgery: Beyond the Traditional Limits	53
1 Introduction	54
2 Portal/Mesenteric Vein Resection	55
3 Arterial Resection	56
4 Extended Lymphadenectomy	57
5 Multivisceral Resection	58
6 Resection for M1 PDAC	58
7 Surgery for Recurrent PDAC	59
8 Pancreatic Parenchyma Sparing Procedures	59
9 Conclusion	60
References	61

Adjuvant Therapy for Pancreatic Cancer	65
1 Introduction	67
2 Rationale for Adjuvant Therapy	67
3 Evidence for Adjuvant Chemotherapy	68
3.1 Systemic Chemotherapy	68
3.2 Regional Chemotherapy	72
4 Evidence for Adjuvant Chemoradiotherapy	73
4.1 Intraoperative Radiotherapy	73
4.2 Postoperative Chemoradiotherapy	73
4.3 Chemoradiotherapy, and Follow on Chemotherapy	74

5	Evidence for Neoadjuvant Therapy	79
5.1	Published Studies	79
5.2	Ongoing Studies	80
6	Evidence from Meta-Analyses	80
6.1	Adjuvant Therapy	80
6.2	Neoadjuvant Therapy	81
7	Conclusions	82
8	Future Directions	82
	References	82

Radiotherapy of the Pancreas: State of the Art in 2012 89

1	The Role of Radiotherapy in the Therapeutic Management of Pancreatic Cancer	90
1.1	Adjuvant Approach	90
1.2	Neoadjuvant Approach	92
1.3	Approach of Unresectable Pancreatic Tumors	93
2	Techniques of Radiation Therapy Planning and Delivery	94
2.1	Radiation Dose Escalation	95
2.2	Intensity-Modulated Radiation Therapy	95
2.3	Image-Guided Radiation Therapy and Stereotactic Body Radiation Therapy	97
3	Conclusions	99
	References	99

Part III Different Cancer Types in the Oesophagus and Stomach

	Adenocarcinoma of the GEJ: Gastric or Oesophageal Cancer?	107
1	Introduction	108
2	Challenges of the Current Barrett's Concept	108
2.1	Evidence of Two Pathways	108
2.2	Evidence of Different Targets for Therapy	110
2.3	Evidence for Surveillance Recommendations	111
	References	112

Why is There a Change in Patterns of GE Cancer? 115

1	Introduction	117
2	An Ageing Population	118
2.1	Factors Leading to Improved Life Expectancy	118
2.2	Implications of an Ageing Population on Management of Upper GI Cancers	118

3	Colonisation with <i>Helicobacter Pylori</i>	119
3.1	Mechanisms of Oncogenesis	119
3.2	<i>H. pylori</i> Eradication and Decline in Prevalence	119
3.3	Association Between <i>H. pylori</i> and Oesophageal Cancers	120
4	The Role of Obesity	120
5	Bile Acids and Dietary Fat	122
6	Tobacco and Alcohol	123
6.1	Smoking and Gastric Cancer	123
6.2	Alcohol, GORD and Oesophageal Cancers	123
7	Gastric Polyps	124
7.1	Epidemiology of Gastric polyps	124
7.2	Adenomatous Polyps and Risk of Malignancy	124
7.3	Hereditary Polyposis Syndromes	125
8	Other Medical Conditions	125
8.1	Pernicious Anaemia	125
8.2	Partial Gastrectomy	126
8.3	Plummer-Vinson Syndrome	126
8.4	Coeliac Disease	127
8.5	Oesophageal Achalasia	127
8.6	Hereditary Tylosis (Familial Palmoplantar Keratosis)	128
9	Anti-Inflammatory Drugs	128
10	Family History	129
10.1	Sporadic Gastric cancer	129
10.2	Inherited Cancer Syndromes	130
11	Having Other Cancers	130
12	Radiation Exposure	131
13	Reduced Immunity	131
14	Work Chemicals	132
15	Hormone Replacement Therapy	132
16	Physical Activity	133
17	Conclusion	133
	References	135

Part IV Choosing the Best Treatment for Oesophageal Cancer

	Endoscopic Treatment for Esophageal Squamous Cell Carcinoma	143
1	Introduction	143
2	Indications of Endoscopic Resection for Esophageal SCC	144
2.1	Absolute Indication	144
2.2	Relative Indications	144
3	Endoscopic Mucosal Resection	145
3.1	Procedures	145
3.2	Advantage and Disadvantage of EMR	145

4	Endoscopic Submucosal Dissection (ESD)	145
4.1	Procedure	145
4.2	Marking and Submucosal Injection	146
4.3	Mucosal incision	146
4.3	Submucosal Dissection	148
4.5	Hemostasis	150
4.6	Prevention of Bleeding	150
5	Complications of Esophageal EMR/ESD	151
	References	153

	Open or Minimally Invasive Resection for Oesophageal Cancer?	155
1	Introduction	156
2	MIO Techniques	157
3	Results	158
4	MIO Learning Curve	163
5	Comments and Future	164
	References	165

	Choosing the Best Treatment for Esophageal Cancer	169
1	Introduction	170
2	Postoperative Mortality	170
3	R0-Resection	171
4	Lymphadenectomy	171
5	Multimodal Treatment	172
6	Adjuvant Therapy	172
7	Neoadjuvant Radiotherapy	172
8	Neoadjuvant Chemotherapy or Radiochemotherapy	173
9	Response Prediction	174
10	Targeted Drugs in Multimodal Therapy	174
	References	175

Part V Multimodal Therapy of GEJ Cancer

	Multimodal Therapy of GEJ Cancer: When is the	
	Definitive Radiochemotherapy the Treatment of Choice?	181
1	Introduction	182
2	Standard Treatment Options in Localized Disease	182
2.1	Perioperative Therapy	182
2.2	Definitive Chemoradiotherapy	182
3	Conclusion	184
	References	184

Radiotherapy of Gastroesophageal Junction Cancer	187
1 Background.	188
2 Diagnostic Workup	189
3 Early Stage Disease	189
4 Locally Advanced Disease	189
5 Neoadjuvant Therapy	190
6 Response-Guided Therapy.	191
7 Definitive Chemoradiation	193
8 Adjuvant Therapy	193
9 Salvage Radiotherapy.	194
10 Palliative Radiotherapy.	195
11 New Radiation Technologies.	195
12 New Combination Possibilities	196
13 Conclusions.	197
References	197

Optimizing Neoadjuvant Chemotherapy Through the Use of Early Response Evaluation by Positron Emission Tomography	201
1 Introduction.	202
2 PET Tracers	203
3 PET for Staging.	203
4 PET and Prognosis.	204
5 PET and Treatment Response	205
5.1 Post-Therapeutic Response Assessment	205
5.2 Pre-Therapeutic Assessment.	206
5.3 Early Metabolic Response	207
6 Conclusions.	208
References	209

Part VI Gastric Cancer

Optimal Surgery for Gastric Cancer: Is More Always Better?	215
1 Introduction.	216
2 Surgical Anatomy	216
3 Characteristics of the Primary Tumour	218
3.1 T1 Disease.	219
3.2 T2 and T3 Disease	221
3.3 T4 Disease.	222
3.4 Extended Lymphadenectomy	223
3.5 Metastatic Disease	224
4 Patient Factors.	225
5 Conclusions.	225
References	226

Can Adjuvant Chemoradiotherapy Replace Extended Lymph Node Dissection in Gastric Cancer?	229
1 Introduction.	230
2 Surgery.	230
3 Chemotherapy	231
4 Chemoradiotherapy	233
5 R1-Resection.	235
6 Conclusion	236
References	237

Predicting the Response to Chemotherapy in Gastric Adenocarcinoma: Who Benefits from

Neoadjuvant Chemotherapy?	241
1 Introduction.	242
2 Histological Response Evaluation	243
3 Histological Tumour Characteristics as a Predictive Marker of Chemotherapy Response.	243
3.1 Efficacy of Neoadjuvant Treatment in SRC Gastric Cancer. . .	244
3.2 Chemoresistance SRC Gastric Cancer: Postulated Mechanisms	245
4 Imaging as a Predictive Biomarker of Chemotherapy Response. . . .	245
4.1 Response Evaluation: EUS and CT.	246
4.2 18-F-Fluoro-2-deoxyglucose Positron Emission Tomography: FDG-PET	246
4.3 Is Response Prediction Improved with Other Radiotracers? FLT-PET.	249
5 Molecular Markers: Predicting Response to Chemotherapy and Targeting Treatment.	250
5.1 Thymidylate Synthase.	250
5.2 Thymidine Phosphorylase and Dihydropyrimidine Dehydrogenase.	252
5.3 Glutathione S-Transferase	253
5.4 p53	255
5.5 Bcl-2.	255
5.6 Survivin	257
5.7 Microsatellite Instability	257
5.8 Inhibition of Angiogenesis: Vascular Endothelial Derived Growth Factor	258
6 Targeted Therapies in Gastric Cancer: Signs of Future Promise. . . .	258
6.1 Tyrosine Kinase Inhibitors.	258
6.2 Monoclonal Antibodies Against VEGF	259
6.3 HER Family	259
7 Conclusions and Future Directions.	261
References	262

Prediction of Response and Prognosis by a Score Including only Pretherapeutic Parameters in 410 Neoadjuvant Treated Gastric Cancer Patients.	269
1 Chapter 1	270
1.1 Background	270
1.2 Prognostic Biomarkers in Gastric Cancer.	271
1.3 Aims of the Study	272
2 Chapter 2	272
2.1 Patients	272
2.2 Clinical Staging	273
2.3 Surgery	273
2.4 Histopathological Work-Up and Response Evaluation.	273
2.5 Statistical Analysis	274
3 Chapter 3	274
3.1 Results	274
3.2 Prognostic Index and Risk Groups	278
4 Chapter 4	280
4.1 Conclusions	280
4.2 Future Directions	284
References	285
Adjuvant Chemotherapy: An Option for Asian Patients Only?	291
1 Introduction.	292
2 Surgery.	293
2.1 Extent of Lymphadenectomy	293
2.2 Epidemiology.	296
2.3 Maruyama Index	296
3 Post/Perioperative Therapy	297
3.1 Adjuvant Chemotherapy	297
3.2 Postoperative Chemoradiotherapy.	301
3.3 Perioperative Chemotherapy	302
4 Conclusions.	303
References	304
Selecting the Best Treatment for an Individual Patient.	307
1 Introduction.	308
2 Treatment of Early Gastric Cancer.	309
2.1 Adjuvant Setting.	309
2.2 Peri-Operative Setting.	311
3 Pharmacogenomics.	314
3.1 Adjuvant Setting.	314
3.2 Peri-Operative Setting.	315
4 Conclusions.	316
References	316